Entitlement Offer To Raise Approximately $3.56 Million
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Market Update
- Suspension from Official Quotation
- Anagrelide Cancer Patent For Japan
- SUDA Signs Additional Licence With Mitsubishi Tanabe
- Half Yearly Report and Accounts
Later from Arovella Therapeutics
- Prospectus For Entitlement Offer
- TGA Approval Granted For ZolpiMist
- Appendix 4C - quarterly
- Anagrelide Cancer Patent For Australia
- Investor Presentation November 2020
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics